• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Aurinia Presents Data on Early Lupus Nephritis Detection & Lupkynis

    BUSINESSWIRE

    Autoimmune drugmaker Aurinia lays off 45% of workforce

    FIERCE PHARMA

    Aurinia Reports Q3 Results & Restructuring for LUPKYNIS® Growth

    BUSINESSWIRE

    Aurinia Pharma Appoints Craig Johnson to Board for Growth Support

    BUSINESSWIRE

    Aurinia Presents LUPKYNIS Data At ASN Kidney Week 2024

    BUSINESSWIRE

    Aurinia Announces Japan Approval of LUPKYNIS® for Lupus Nephritis

    BUSINESSWIRE

    Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

    BUSINESSWIRE

    Aurinia Announces Board Restructuring

    BUSINESSWIRE

    Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

    BUSINESSWIRE

    Aurinia To Participate In H.C. Wainwright Conference

    BUSINESSWIRE

    Aurinia Shareholder Calls For CEO And Two Directors To Resign

    BUSINESSWIRE

    Aurinia Reports Q2 And H1 2024 Financial And Operational Results

    BUSINESSWIRE

    Aurinia To Release Q2 Results And Operational Update On August 1, 2024

    BUSINESSWIRE

    ILJIN SNT Calls On Aurinia Board To Honor Shareholders` Voices From AGM

    BUSINESSWIRE

    Aurinia to Participate in Upcoming Investor Healthcare Conferences

    BUSINESSWIRE

    Aurinia Announces 2024 Annual General Meeting Results

    BUSINESSWIRE

    ILJIN SNT To Vote Against Aurinia Revised Equity Incentive

    PR NEWSWIRE

    Aurinia: LUPKYNIS Profile In Lupus Nephritis At EULAR 2024

    BUSINESSWIRE

    Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

    BUSINESSWIRE

    Aurinia Provides Update on Proxy Statement

    BUSINESSWIRE

    Shareholder Urges Withholding Support For Aurinia CEO Greenleaf

    BUSINESSWIRE

    Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

    BUSINESSWIRE

    Analysis Shows LUPKYNIS Cost-Effective For Lupus Nephritis At NKF Meeting

    BUSINESSWIRE

    Aurinia LUPKYNIS Lupus Nephritis Data At Rheumatology Congress

    BUSINESSWIRE

    Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

    BUSINESSWIRE

    Aurinia Shareholder Urges Board Action To Enhance Value

    BUSINESSWIRE

    Aurinia Reports Q1 2024 Financial, Operational Results

    BUSINESSWIRE

    Aurinia Initiatives For Lupus Nephritis Awareness Month

    BUSINESSWIRE

    Aurinia brings singer Toni Braxton to Lupus Awareness Month push

    FIERCE PHARMA

    FDA Approves Updated LUPKYNIS® Label With Long-Term AURORA Data

    BUSINESSWIRE

    Updated Aurinia Presentation At Bloom Burton Investor Conf 2024

    BUSINESSWIRE

    Aurinia Q1 2024 Financials, Operations On 5/2

    BUSINESSWIRE

    Aurinia Receives Exemptive Relief from Canadian Securities Regulators

    PRESS RELEASE

    Aurinia to Participate in Upcoming Investor Healthcare Conferences

    BUSINESSWIRE

    Aurinia stock downgraded by Bloom Burton amid strategic challenges

    PRESS RELEASE

    Aurinia Discloses 2023 Year-End Financial and Operational Results

    BUSINESSWIRE

    After hunt for buyer fails, Aurinia lays off 25%, drops R&D

    FIERCE BIOTECH

    Aurinia to Release 2023 Fourth Quarter and Full Year Financial Results

    BUSINESSWIRE

    Aurinia Provides Preliminary Unaudited Fourth Quarter Net Revenue Results

    BUSINESSWIRE

    Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

    BUSINESSWIRE

    Aurinia Announces Collaboration Partner Otsuka Filed NDA for LUPKYNIS

    BUSINESSWIRE

    Aurinia Reports Third Quarter and Nine Months 2023 Financial Results

    BUSINESSWIRE

    Aurinia Presents Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS

    BUSINESSWIRE

    Aurinia Response in Support of 2023 Updated EULAR Recommendations

    BUSINESSWIRE

    Aurinia Pharma to Release Third Quarter Financial Results on November 2, 2023

    BUSINESSWIRE

    Aurinia Pharmaceuticals Announces Presentations at ASN Kidney Week 2023

    BUSINESSWIRE

    Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director

    BUSINESSWIRE

    Aurinia quells investor unrest, names former CEO Foster to board

    FIERCE PHARMA

    Aurinia Appoints Board Directors with Deep Experience in BioPharma Leadership

    BUSINESSWIRE

    Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial

    BUSINESSWIRE

    Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

    BUSINESSWIRE

    Aurinia BOD Announces Exploration of Alternatives to Maximize Shareholder Value

    BUSINESSWIRE

    Aurinia will explore possible sale, following push by shareholder

    ENDPTS

    Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) a

    BUSINESSWIRE

    LUPKYNIS Achieved Higher Renal Response in Lupus Nephritis Patients

    BUSINESSWIRE

    Aurinia Files Form S-8 to Register Shares Underlying Disclosed Inducement Awards

    BUSINESSWIRE

    Aurinia Announces 2023 Annual General Meeting Results

    BUSINESSWIRE

    Aurinia’s board gets pushback from another shareholder

    ENDPTS

    Aurinia Pharmaceuticals Reports 1Q 2023 Financial and Operational Results

    BUSINESSWIRE

    Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®

    BUSINESSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.